4) The catheter is fixed to the neighbouring skin by two linen sutures.
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(4) The catheter is fixed to the neighbouring skin by two linen sutures.
(5) A strip of skin is marked out leading from the urethral orifice to the tip of the penis, where it is intended the new meatus shall be.
(6) The skin on the sides of the strip is raised widely. (7) An incision is made down the dorsum of the penis, and spread widely.
(8) Punctures are made in the scrotum on either side to allow free exit of serum, which otherwise causes cedema.
(9) The double stop sutures are inserted with care to leave one-eighth of an inch slack in them. This avoids any risk of sloughing the fragile skin by pressure.
(10) The edges of the skin approximated by the double-stop sutures are joined by the finest possible catgut stitches.
(11) The wounds are sprayed with sulphonamide and penicillin powder and left open to the air.
(12) The catheter is connected to a thin plastic tube, led into a bottle on the floor. This gives suction drainage of the bladder.
(13) After eight days the double stop sutures are removed by cutting between the aluminium and the glass beads.
(14) After ten days the Malecot catheter is removed, and the child allowed up. I have found this technique extraordinarily free from the troubles and disappointments I encountered when using other methods, including the modification of Edmunds' technique which I published in the Lancet (1936) , i, 141. It has been used now in over 50 cases. One of these (not done by me) had a persistent perineal fistula three months after operation. If this does not close spontaneously I anticipate no great difficulty in mending it by operation. Another developed a penile fistula, owing to the snipping off of a piece of skin when removing a more primitive type of stop suture. This has since been mended. A third, not done under my supervision, broke down owing to insufficient freeing of the lateral flaps, but at a second attempt healed completely. Apart from these 3 cases there have been no serious troubles and all the cases treated are now passing urine in the normal male manner. [March 23, 1949] The Use of Irradiation, Surgery and Hormones in Breast Cancer By FRANK E. ADAIR, A.B., M.D., F.A.C.S., Hon.D.Sc., Hon.LL.D.
Attending Surgeon, Memorial Hospital, New York, N.Y. THE study and treatment of cancer of the breast to-day involves a knowledge of all, not only surgery, irradiation, and hormones but also a minimum of genetics and biochemistry. There is no field of human cancer where the personnel of research laboratories are working so feverishly as in breast cancer. Fortunately the disease in laboratory animals lends itself to laboratory experiment in many different directions.
CASES
Our clinical material at the Memorial Hospital consists of 13,054 cases of breast cancer; 8,623 female patients were considered operable. There were 125 cases of breast cancer in the male; and there were 48 cases of sarcoma of the mammary gland.
Our material for this study consists of 3,988 cases during the 8 years 1935 to 1942 inclusive. It is to be found in Table I (opposite). Our operable material is improving from year to year; we think this is the result of continuous education and propaganda on early detection of cancer by the American Cancer Society.
X-RAY THERAPY ALONE
For palliation, X-ray has a prime and honoured place in breast cancer. However, its effectiveness as a single agent in the cure of operable mammary cancer is approximately half that of radical surgery. We treated 125 operable cases of breast cancer employing heavy high voltage X-rays. In every case, we had a positive microscopic report of cancer by aspiration biopsy, before instituting therapy. With the 250 kV machine, varying doses were given through five portals, cross-firing the breast, the axilla and supraclavicular areas. The sum total to each portal averaged approximately 3,000 r. This was the complete therapy. The five-year salvage in that series treated by X-ray alone, in contrast to another series being treated at the same time by pre-operative irradiation, followed by radical surgery, was 26% versus 50%. There is, therefore, no comparison as to final effectiveness of the two modalities of therapy. One might ask why the X-ray dosage was not increased to a cancericidal dose instead of leaving it at 3,000 r. In many instances the cancer was completely necrosed by such therapy as was given depending much on the microscopic grade of the cancer. In other cases, however, the cancer was still viable even after being cross-fired through two portals in some cases by as much as 3,600 r each. At the therapy level of approximately 3,000 r we began running headlong into trouble. Experience teaches us that the cancericidal dose for breast cancers which are radio-resistant is between 5,000 r and 6,000 r. However, it is not possible to apply this amount of radiant energy to the covering of the chest wall without obtaining fragility of the underlying ribs, clavicle and scapula. It is, therefore, not feasible as a rule to rely on X-ray therapy to cure operable breast cancer because of the difficulty of delivering a cancericidal dose by X-rays without causing great damage to skin, ribs, clavicle, lungs and scapula.
Curiously the involved axillary nodes are affected by irradiation in a very unequal manner. The effect on individual nodes involved with cancer is not the same with each node even though all conditions of therapy are identical One node replaced with cancer may be so damaged as to be completely necrotic, the result of irradiation; while another node, exactly the same size, and in the same field, receiving the same tissue dose of X-rays, may be completely viable. This fact reveals my basis of reasoning and my answer to those who wish to do a simple mastectomy, and depend on the X-rays to destroy the axillary disease.
It cannot be relied on. 
PRE-OPERATIVE IRRADIATION
The controversy is still raging in some countries as to the value ofpre-operative irradiation. In an effort to evaluate it, for a period of five years (1935 to 1940) , we subjected the operable cases of breast cancer to pre-operative irradiation after first establishing that it was breast cancer by aspiration biopsy. During the five years, we employed differing amounts of X-ray therapy, varying from 1,200 r to 3,600 r per portal; The difficulties of performing the operation multiplied with the increased amount of X-ray dosage. Eventually we obtained very poor wound healing, in those who had over 3,000 r per portal. The radical amputation was made at varying times depending on the healing of the skin after the irradiation. In some instances, we operated one month after the X-ray therapy, while in others, we were unable to operate before six months. This delay factor was important. The five-year results of cure, by giving pre-operative irradiation followed by the radical, were mildly disappointing. I had anticipated that the results would be improved. The survival rate of those operable cases having disease confined to the breast, treated by pre-operative irradiation followed by radical surgery, was 74-9 %-in contrast to those treated by the immediate radical 82-2%. And similarly those having disease in the breast and axilla, 40-7% versus 43-5% (see Table II ). This experiment was therefore costly in human lives but at least in America it largely sounded the death knell of pre-operative irradiation. One of the great errors was that many who had strongly advocated the use of pre-operative irradiation had diagnosed their cases only on clinical grounds, rather than proving the diagnosis by biopsy.
IMMEDIATE RADICAL MASTECTOMY FOLLOWED BY IRRADIATION
Following the five-year experiment ofpre-operative irradiation followed by radical surgery, we next turned to the immediate radical mastectomy, which we have been doing since then.
If the patient has no microscopic involvement of the axilla we rest our case on surgery alone. Because of the fact that axillary involvement implies a fairly desperate situation, u%e give post-operative irradiation in those cases having such axillary involvement. If they still menstruate, we give X-ray castration.
The improvement in our five-year cures by this method, over the previous five-year method of pre-operative irradiation followed by radical surgery, is encouraging and even striking. It has given us a renewed faith in surgery.
Our increased rate of cure is due to two factors: Improvement in surgery, the care of the patient and X-ray therapy; and in addition the effectiveness of the campaign to educate the public on early signs of cancer.
A comparison of the results of therapy follows: Table II demonstrates the price of delay which is necessary if a thorough course of preoperative irradiation is to be delivered. This is shown in the groups having axillary involvement where the gain by performing the immediate radical (as against pre-operative irradiation) goes from 43 5 % to 40 7%; and involvement in the breast alone from 82-2y% to 74 9%.
The latter group is particularly striking.
Because the end-results in our experience have proven better by the method of immediate radical mastectomy followed by post-operative therapy, we are now pursuing this course.
We do not know if post-operative X-ray therapy adds anything to salvage. It has always been my impression that post-operative X-ray therapy added from 3 to 5°,, but as far as we know, no one has carried out the experiment of comparing the results of operable cases where radical surgery alone was employed, with a similar number of cases where the radical was followed by X-ray therapy-in the same hands or clinic. For some time we have wanted to make this comparison, but at the time we wished to start, hormone therapy came into view, and we were more anxious to start on the hormone experiment of introducing testosterone pellets into the surgical wound at the time of the radical mastectomy, so we did not carry out the former experiment.
However, it is very important that an evaluation of the exact amount accomplished by post-operative irradiation be determined. If it has no value, it is important that we stop post-operative irradiation because it definitely adds to the post-operative aedema of the arm.
HORMONE THERAPY The work of the British investigators in the aestrogen field has been most fruitful, and under the influence of Haddow will go far toward arriving at vital conclusions.
Haddow and his co-workers in 1944 were the first to describe the use of the synthetic cestrogens diethylstilbeestrol and triphenylchlorethylene, in a number of neoplastic diseases which included bladder, rectum, testes, breast, &c., and in that same year the Section of Radiology of the Royal Society of Medicine presented a discussion of cases of advanced breast cancer receiving the synthetic cestrogens (Proc. R. Soc. Med., 37, 731).
A Joint Scientific Committee on the use of oestrogens in cancer was formed for the co-ordination of this work by the British Empire Cancer Campaign and the Royal Society of Medicine.
For this type of co-operative effort in America, a sub-committee of the Therapeutic Trials Committee, of the American Medical Association, was set up. There are four of us on this Committee with a permanent secretary or co-ordinator. Our supplies of androgens and cestrogens are distributed and given free to about 20 groups of workers who periodically report. The X-ray films, pathological slides, histories, and follow-up reports go eventually to the Army Medical Museum in Washington, where we of the Committee meet and study the material with our X-ray consultants and consultant pathologists.
At Memorial Hospital we have had experience with both the androgens and oestrogens but we have healed a greater number of advanced breast cases with testosterone.
Credit for first suggesting the use of testosterone in breast cancer should go to Dr. A. A. Loeser, a London gynaecologist. Curiously enough both Loeser and P. Ulrich had an article on the subject in the same issue of Acta Unio Internationalis Contra Cancrum, in 1939. Loeser, however, followed up his primary suggestion with 6 additional case reports in 1941. Next year, 1942, my associate, Dr. J. H. Farrow, together with our chemist Dr. H. E. Woodard, made a report. They used small doses, 5 to 25 mg. three times weekly. Loeser, in describing their contribution, states: "Unfortunately he used only small quantities and had no results. He even saw an unfavourable effect with the doses he administered on skeletal metastases." Farrow and Woodard were the first, howe.er, to call attention to the hypercalcxmia which occasionally took place under the influence of testosterone therapy.
Fels, in 1944, was the first to demonstrate that improvement in the destroyed areas of bone had taken place in one of his 3 cases. In the sa7me year we had treated 48 private patients, using 25 mg. of testosterone propionate daily, and had been impressed by the occasional response in this group, particularly those cases with bony metastases. One case with brain metastasis had projectile vomiting; one had chest metastasis, and one liver metastasis. We felt that the possibilities of this hormone would not be known until larger doses of this expensive drug were employed than had been heretofore. We therefore stepped our dosage up to 200 mg. daily in the beginning, and varied the dose from time to time. We made our first report in 1946. We confirmed the Fels' report of his one case ofimprovement of bone metastasis. Our X-ray films demonstrated bone repair in several cases.
We organized a hormone team at the hospital, formed for the purpose of making further exploration into the effects of the steroids on human cases of advanced breast cancer. The team consists of the following 12 persons: the principal investigator, 2 associate surgeons, 2 research fellows, 1 consultant on steroid chemistry, 1 physiological chemist, 1 radiologist, 1 clinical fellow, a full-time nurse, a full-time social worker, and a secretary.
We have used different cestrogens, but to date our most satisfactory cestrogen is stilbcestrol.
We have chiefly used testosterone propionate by injection. Our conclusion concerning methyl testosterone is that it is not so effective as the propionate.
In order to ascertain the effect of prophylactic doses, we have also employed testosterone propionate in the wound of approximately 500 radical mastectomies. We are not yet ready to report on these cases, except to say that, as a result of inserting four pellets into the lattissimus dorsi muscle, a total of 300 mg. in each case, the patients lost their periods, varying from three months to six months. Those who were near their menopause sometimes lost their periods permanently.
Our Memorial Hospital hormone team has the following to report on clinical studies: 
LABORATORY RESULTS
Of the 21 patients with bone metastasis showing a pre-treatment hypercalcamia, 15 or 71 % showed a significant drop in the serum calcium during the first three months of treatment with testosterone propionate. 23 % of our cases treated by testosterone propionate had an elevation of the calcium. During the first three months of treatment 63 % of patients with bone metastasis had an increase in the serum alkaline phosphatase above the pre-treatment level, falling later. There was little change in those patients without bone metastasis.
The serum inorganic phosphorus decreased significantly during therapy by testosterone or ethinyl cestradiol.
Pathologists of experience in the neoplastic field find that in those cases treated over a long period by the cestrogens there is little difference in the microscopic picture between a mammary cancer destroyed by irradiation or by cestrogens. In some cases treated by prolonged oestrogen therapy, there is no remaining trace of cancer, when compared with the biopsy slide taken before the therapy started. There is nuclear and cytoplasmic disintegration with the laying down of voluminous fibrosis.
It is interesting to note that the repair processes of cases with bone metastasis treated by the X-rays and by the hormones give no clue as to which type of therapy was employed.
In the stratified squamous epithelium of the cervix the cytoplasmic glycogen content either increased or remained elevated in one-half of the cases during androgen or cestrogen treatment.
Of 37 liver cases studied, 15 patients, or 41°0, had diminished liver function in two or more tests (serum bilirubin, hippuric acid synthesis, thymol turbidity and cephalin flocculation).
We have come to the conclusion that in those cases with hypercalclmia in which the administration of testosterone therapy makes them very ill the condition is probably due to renal damage. The kidneys probably are unable to handle the elimination of heavy amounts of calcium: our cases in which this occurred had impaired function. We have seen cases of marked liver involvement with jaundice present temporarily clear up under testosterone therapy, and have seen the liver go back to the costal margin after being well below it. In liver metastasis the alkaline phosphatase sometimes goes as high as 55 mg.
We have had two cases of abdominal metastasis, with scattered masses present, accompanied by fluid requiring frequent tappings, regress under testosterone therapy. In one case the masses and fluid disappeared for a period of six months.
Nathanson reports that with large doses of cestrogen 37 % with pulmonary metastasis felt improved, and 42% showed X-ray evidence of improvement. This appears very high but Nathanson uses enormous doses of oestrogen up to 200 mg. daily.
HAEMATOLOG1C CHANGES (ANDROGEN THERAPY) Seventeen of 70 cases showed an increase of hemoglobin of at least 26%. Several cases exhibited a 100% increase. 10 patients demonstrated a rise to levels between 16 and 20 grammes. Complete hematologic work-up including bone-marrow and simultaneous blood chemistry studies were performed on the latter group of 10 patients. 6 of these patients exhibited increased bone-marrow activity and an increase in erythro-myelo ratio. None of these 6 patients had pulmonary or pleural metastases. No htematinics were given. All of these patients were treated with testosterone propionate. Dosage level ranged between 200 and 300 mg. per week. Bone-marrow studies were done between seventeen and eightythree weeks after the institution of androgen therapy.
IMPROVEMENT AFTER CESSATION OF HORMONE THERAPY It was noted that all patients on testosterone propionate therapy who demonstrated objective improvement did so for a variable temporary period. The period was then followed by a worsening of the disease and an increase in symptoms.
Our experience with cessation of therapy, beginning in July 1947 in one case and extending now to a total of 8 patients, has demonstrated a second period of improvement in 6. All have been off therapy at least two months.
This group of 8 patients had been on androgen for periods ranging from ten to twenty-four months and had received total dosages varying from 12,000 to 19,000 mg.
A possible hypothesis is that of tumour adaptation to an androgen environment, and that cessation of therapy again produces endocrine unbalance. It might even be advisable to switch to an cestrogen.
Although striking clinical improvements such as cessation of pain and disability, the need for narcotics, &c., take place many times within three or four weeks, it seems to me that our cases which have had enormous doses of testosterone propionate, such as 15 to 20 grammes, are the most impressive. Those patients who lived long enough to get a large dose of testosterone took on generally the physical characteristics of males. And it is possible that they got male characteristics which were fixed and irreversible, thus making further growth of mammary cancer an impossibility.
This viewpoint might explain why the 6 cases after having had very large doses of testosterone, and at one point having had renewed growth of the tumour, improved after stopping the injections.
One such case is the following: November 25, 1946 , at which time a total of 9,775 mg. of androgen had been given. At this time a dosage of 100 mg. 3 times a week was started. In March 1947 the patient began to deteriorate, and roentgen castration was given with resultant symptomatic relief of one month's duration. Androgen therapy was continued. X-rays in June 1947 demonstrated progression of osseous metastases. Patient developed a paraplegia in June 1947, severe spinal column pain, rectal and urinary incontinence with impaired sensation from the level of umbilicus downward. This was due to the crushing of a thoracic vertebra. Testosterone propionate was stopped July 31, 1947, after a total of 18,800 mg.
Neurologic pathology began to improve by the end of August 1947. Rectal and urinary control returned in November 1947, and with diminution in pain, narcotic requirements diminished. Complete function returned after eight months at which time narcotics were discontinued. Repeated X-rays taken as recently as February 1949 reveal no progression of osseous metastases. Patient has had no hormone therapy for twenty months, and she is doing her own housework. Patient has been under observation for four years.
Her dense bony repair of the left alatof the sacrum at the end of four years is interesting (see fig. 1 ).
FIG. I.-On admission four years ago there was almost complete absorption of the left ala of the sacrum, with inability to walk or stand without great pain. Under testosterone therapy dense callous was laid down at this site as revealed by the X-ray film taken four years later. The area of repair is more dense than the surrounding normal bone. All clinical symptoms of previous bone destruction are gone.
Our experience with cestrogen has not been as striking as this. Our dosage for stilboestrol is 15 mg. daily for an indefinite period. We have found that cestrogen therapy in many cases requires months before improvement takes place. However, we have seen epithelialization of a cancer ulcer take place within five weeks in one case.
Our dosage at present for testosterone propionate is 100 mg. three times a week given for an indefinite time. We have no suggestion at present as to how to overcome all the unpleasant side-effects. However, there is every probability that a new chemical agent will be developed which will have the same beneficial effect without the mentally distressing side effects.
There are approximately six hundred chemical compounds which should be investigated on human cases of breast cancer. I think we must look chiefly to the steroid chemists and the endocrinologists to be the leaders in this lengthy investigation. We clinicians can be of great help but the endocrinologist is more apt to see the weakest link in the endocrinological chain. During the past five years it has been demonstrated that the life-history of breast cancer has been profoundly altered. I have every belief that great contributions will continue to be made in the next few years.
